Factors Affecting Adherence to Co-Trimoxazole Preventive Therapy in HIV/AIDS Patients Attending an Antiretroviral Therapy Clinic in Ethiopia University Hospital: A Cross-Sectional Study

References

• Gayle HD, Hill GL. Global impact of immunodeficiency virus and AIDS. Clini Microbiol Rev. 2001;14(2):327–335. doi:10.1128/CMR.14.2.327-335.2001
   PubMed Web of Science ®Google Scholar
• Federal Democratic Republic of Ethiopia. Country progress report on the HIV response. September, 2014.
   Google Scholar
• Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health; Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. 2008.
   Google Scholar
• Lowrance D, Makombe S, Harries A, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr. 2007;46:56–61.
   PubMed Web of Science ®Google Scholar
• Suthar AB, Granich R, Mermin J, et al. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ. 2012;90:128C–138C. doi:10.2471/BLT.11.093260
   PubMed Web of Science ®Google Scholar
• HAPCO.HIV prevention in Ethiopia National Road map; 2018. Available from: https://ethiopia.unfpa.org/en//hiv-prevention-Ethiopia-national-road-map. Accessed May 14 2020.
   Google Scholar
• World health organization guideline on Post-Exposure Prophylaxis for HIV and Use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach: december 2014 supplement of the 2013 consolidate ARV guidelines. Available from: https://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_dec2014/en/. Accessed May 14, 2020.
   Google Scholar
• Mermin J, Lule J, Ekwure JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality,CD4cell count and viral load in HIV in rural Uganda. Lancet. 2004;364(9443):1428–1434. doi:10.1016/S0140-6736(04)17225-5
   PubMed Web of Science ®Google Scholar
• Grimwade K, Sturm A, Nunn A, Mbatha D, Zungu D, Gilks C. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS. 2005;19:163–168. doi:10.1097/00002030-200501280-00008
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994;120:932. doi:10.7326/0003-4819-120-11-199406010-00006
   PubMed Web of Science ®Google Scholar
• Musembi J, Determinants of adherence to cotrimoxazole preventive therapy among hiv infected persons on treatment in Machakos District Hospital, Machakos County, Kenya 2014. Available from: https://ir-library.ku.ac.ke/handle/123456789/13745. Accessed May 14, 2020.
   Google Scholar
• Simon M. Factors Affecting Adherence to Cotrimoxazole Prophylaxis Among HIV/AIDS Patients in Rukungiri District. Uganda; 2009. Available from: http://makir.mak.ac.ug/handle/10570/992. Accessed May 14, 2020.
   Google Scholar
• Denue BA. Knowledge regarding co-trimoxazole preventive therapy among patients who are HIV positive in a tertiary health facility, northwestern Nigeria. Sub-Sharan Afr J Med. 2017;4:31–36. doi:10.4103/ssajm.ssajm_22_16
   Google Scholar
• Eldred LJ, Wu AW, Chaisson RE, Moorev RD. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr. 1998;18:117–125. doi:10.1097/00042560-199806010-00003
   Web of Science ®Google Scholar
• Kasirye G, factors affecting adherence to cotrimoxazole prophylaxis in HIV infected exposed children attending MUJHU AIDS clinic at Mulago hospital. [dissertation]. Makere medical school. 2006:
   Google Scholar
• Gebresillassie BM, Gebeyehu MB, Abegaz TM, et al. Evaluation of cotrimoxazole use as a preventive therapy among patients living with HIV/AIDS in Gondar University Referral Hospital, northwestern Ethiopia: a retrospective cross-sectional study. HIV AIDS. 2016;8:125. doi:10.2147/HIV.S103081
   Google Scholar
• WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach; 2013. Available from: https://www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed May 14, 2020.
   Google Scholar
• Napolitano F, Napolitano P, Angelillo IF. Medication adherence among patients with chronic conditions in Italy. Eur J Public Health. 2016;26(1):48–52. doi:10.1093/eurpub/ckv147
   Web of Science ®Google Scholar
• Sahm. L, MacCurtain A, Hayden J, Roche C, Richards HL. Electronic reminders to improve medication adherence—are they acceptable to the patient? Pharm World Sci. 2009;31:627–629. doi:10.1007/s11096-009-9327-7
   PubMed Web of Science ®Google Scholar
• Ahmed R, Aslani P. What is patient adherence? A terminology overview. Int J Clin Pharm. 2014;36:4–7.
   PubMed Web of Science ®Google Scholar
• Bardfield J, Agins B, Palumbo M, Wei AL, Morris J, Marston B. Improving rates of cotrimoxazole prophylaxis in resource-limited settings: implementation of a quality improvement approach. Int J Qual Health Care. 2014;26(6):613–622. doi:10.1093/intqhc/mzu085
   Web of Science ®Google Scholar
• Moodley D, Reddy L, Mahungo W, Masha R. Factors associated with coverage of cotrimoxazole prophylaxis in HIV- exposed children in South Africa. PLoS One. 2013;8(5):e63273. doi:10.1371/journal.pone.0063273
   Web of Science ®Google Scholar
• Landovitz RJ. What’s the best way to measure ART adherence? J Watch. 2011;23(3).
   Google Scholar
• Vreeman RC, Wiehe SE, Pearce EC, Nyandiko WM. A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries. Ped Infect Dis J. 2008;27(8):686–691. doi:10.1097/INF.0b013e31816dd325
   PubMed Web of Science ®Google Scholar
• Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 2010;5(1):70–77. doi:10.1097/COH.0b013e328333ad61
   PubMed Web of Science ®Google Scholar
• Chesney MA. The elusive gold standard: future perspectives for HIV adherence assessment and intervention. J Acquir Immune DeF Syndr. 2006;43(1):S149–S155. doi:10.1097/01.qai.0000243112.91293.26
   PubMed Web of Science ®Google Scholar